AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05655169 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Piezosurgery and GaALAs diode laser
Description: One incision will be made between the roots of the six upper anterior teeth, and two incisions will be made between the upper canines and the second premolars. The incisions will be 5 mm long and start 4 mm apical to the interdental papilla.~After six weeks of piezosurgery, GaALAs diode laser (wavelength: 810 nm and exposure time of 10 seconds\\point) 10 seconds per point will be applied.
Study NCT05655169 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Piezosurgery
Description: One incision will be made between the roots of the six upper anterior teeth, and two incisions will be made between the upper canines and the second premolars. The incisions will be 5 mm long and start 4 mm apical to the interdental papilla.
Study NCT05655169 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fixed orthodontic appliance
Description: After the levelling and alignment phase is completed, the rectangular stainless steel archwires (0.019 × 0.025) will be inserted, then after two weeks, the en masse retraction will be started via closed nickel-titanium coil springs applying 250 g of force per side.
Study NCT02021318 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roxadustat
Description: Oral tablet.
Study NCT02484625 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cheese
Description: Commercially available cheese, 180 kcal
Study NCT02891993 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IMPROVED
Description: The electronic symptom monitoring intervention, Improving Management of Patient-Reported Outcomes Via Electronic Data (IMPROVED), consists of patients self-reporting their symptoms each day using a tablet computer. At morning rounds each day, the clinical team will view reports detailing their patients' symptom burden.
Study NCT02891993 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Participants receiving usual care will also self-report their symptoms each day using tablet computers. However, these patients' clinicians will not receive their symptom reports. Patients randomized to usual care will report their symptoms to their clinicians as they usually would, at their own discretion.
Study NCT03921892 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Parenting Education
Description: Parenting education such as positive parenting interactions with their child, knowledge of developmental milestones and interactions with the child to support that development, as well as co-parenting skills will be provided either in-person or on-line to adolescent fathers
Study NCT03921892 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Parenting Education
Description: Parenting education such as positive parenting interactions with their child, knowledge of developmental milestones and interactions with the child to support that development, as well as co-parenting skills will be provided either in-person or on-line to adolescent fathers
Study NCT02252952 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Beverage Consumption
Study NCT02484625 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Milk
Description: Commercially available milk, 180 kcal
Study NCT00377130 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self Administered Stress Management
Description: The SSMT kit includes a DVD and booklet will discuss the sources and manifestations of stress during chemotherapy and the potential benefits of stress management training. The videotape/DVD and booklet will also include brief instruction in paced breathing, progressive muscle relaxation with guided imagery, and use of coping self-statements as well as recommendations for practicing the techniques before the start of chemotherapy and using them after the start of treatment. The exercise combines abbreviated progressive muscle relaxation training with use of relaxing mental imagery. The positive thinking exercise provides participants with brief instruction in the use of coping self-statements using techniques borrowed from stress inoculation training.
Study NCT02021318 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Darbepoetin alfa
Description: Subcutaneous or intravenous injection.
Study NCT02252952 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Beverage Consumption
Study NCT00483951 — intervention group
Intervention type: DEVICE
Intervention: Toshiba Aquilion ONE CT
Description: The Toshiba Aquilion ONE CT system has the ability to acquire whole organ volume images in a single rotation by utilizing an x-ray detector that is configured as 320 detector rows with a 0.5 mm width, providing a z-axis coverage of 16 cm of anatomy.
Study NCT00483951 — intervention group
Intervention type: DEVICE
Intervention: SWiemens MRI scanner
Description: Investigational or research MRI coils may be used in the protocol. The coils are noninvasive devices external to the body. The coils act as antennae to receive small radiofrequency signals out of the body. Coils of the type we use are used daily in clinical MRI practice.
Study NCT02049528 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-122
Description: CC-122
Study NCT03196284 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eptacog alfa
Description: A single dose of 90 μg/kg eptacog alfa one week after dosing with concizumab. On-demand treatment during bleeding episodes in both treatment arms
Study NCT03196284 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eptacog alfa
Description: A single dose of 90 μg/kg eptacog alfa one week after dosing with concizumab. On-demand treatment during bleeding episodes in both treatment arms
Study NCT04654182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine Gluconate
Description: Product used in accordance with manufacturers Hand Hygiene instructions
Study NCT02140320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RV1729 single dose
Description: Safety and tolerability of single dose
Study NCT02140320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RV1729 matching placebo single dose
Description: Safety and tolerability of single dose
Study NCT01602666 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-Dimensional Conformal Radiation Therapy
Description: Undergo 3D-CRT
Study NCT01602666 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV
Study NCT02140320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RV1729 14 day repeat dose
Description: Safety and tolerability of repeat doses
Study NCT01602666 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV
Study NCT01602666 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: Given IV
Study NCT02140320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RV1729 matching placebo 14 day repeat dose
Description: Safety and tolerability of repeat doses
Study NCT02140320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RV1729 28 day repeat dose
Description: Safety and tolerability of repeat doses
Study NCT02140320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RV1729 matching placebo 28 day repeat dose
Description: Safety and tolerability of repeat doses
Study NCT02016066 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CR6261
Description: CR6261 50 mg/kg solution will be administered as a single 2-hour intravenous infusion
Study NCT01924403 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vertical Mattress Closure
Study NCT01924403 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Running Subcuticular Closure
Study NCT02885519 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IBBIS mental health care and standard vocational rehabilitation
Description: Standard vocational rehabilitation.~Stepped mental health care provided by the IBBIS mental health care team (e.g. nurses, psychologists and medical doctors) with the treatment modalities:~Psychoeducation Bibliotherapy Stress-coaching Mindfulness-based stress reduction Monitoring and re-assessment
Study NCT02885519 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrated mental health care and vocational rehabilitation
Description: Integrated mental health care and vocational rehabilitation provided by the IBBIS team. The IBBIS team is composed by employment specialists from the municipal job centers and health care professionals from the mental health services (e.g. nurses, psychologists, and medical doctors).~Mental health care is provided according to a stepped care model with the following treatment modalities:~Psychoeducation Bibliotherapy Stress-coaching Mindfulness-based stress reduction Monitoring and re-assessment~Vocational rehabilitation is inspired by Individual Placement and Support and is a workplace-oriented intervention with problem-solving conversations as a core element
Study NCT01602666 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiation Therapy
Description: Undergo IMRT
Study NCT03014388 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: autogenous bone
Description: Autogenous bone graft (gold standard). sinus lift with autogenous bone.
Study NCT03014388 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mineralized plasmatic matrix
Description: By using venoud blood from the patient, together with bone graft, a centrifuge will be used to obtain the top layer after centrifuging blood at 3000 RPM.
Study NCT01740427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-0332991
Description: PD-0332991, 125mg, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment
Study NCT01740427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Letrozole, 2.5mg, orally once daily (continuously)
Study NCT01740427 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo, 125mg, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment
Study NCT01740427 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole
Description: Letrozole, 2.5mg, orally once daily (continuously)
Study NCT03603990 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vitrectomy
Description: During the first 6 month :Only Panretinal photocoagulation(if high-risk PDR or rubeosis iridis) may be given.~After First Six Months : All therapies for DME may be given at the discretion of the investigator
Study NCT02016066 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered as a single 2-hour intravenous infusion
Study NCT03603990 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Patients with usual care according to the investigator choice :~During the first 6 month : All therapies for DME may be given at the discretion of the investigator during the study, except a vitrectomy.~After First Six Months : All therapies for DME may be given at the discretion of the investigator, including a vitrectomy.
Study NCT01736007 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 308-nm excimer laser to alopecia patch
Description: MED dosing as per protocol with beginning at 50 mJ/cm2 below MED with increases by 50mJ/cm2 every 2 treatments as tolerated. Maximum dosing would be 850mJ.Treatments given twice a week for 12 weeks.
Study NCT01736007 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Liquid light guide tip on laser
Description: Sham treatment involves placement of liquid light guide tip developed by the laser company which attaches to the end of the hand wand and blocks the laser light from passing to the target. Patients are treated twice a week for 12 weeks.
Study NCT02280707 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Grab a Cup, Fill it Up
Description: The intervention involved installing promotional posters encouraging students to drink water as well as cup dispensers stocked with disposable 5 ounce cups near water fountains in school lunchrooms.
Study NCT01521780 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MRI
Description: Participants undergo volumetric \& diffusion weighted (DW) MRI. Participants are scanned twice, with an intervening fifteen minute walk between the scans.
Study NCT01521780 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pathology
Description: Participants who are undergoing surgical resection of HCC per their standard of care treatment, will submit tumor samples for biomarker analysis.
Study NCT03166631 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 891065
Description: Part A, Part B
Study NCT01521780 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood Samples
Description: Blood is collected from participants during screening Visit 1 - 24.5 ml. During Visit 3, blood samples totaling 22 ml, are collected at least 6-18 hours post-resection, and every other day up to a week until discharge. At follow up Visit 4, 5.5 ml of blood is collected.
Study NCT01521780 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood Samples
Description: Blood is collected from participants during screening Visit 1 - 24.5 ml, and follow up Visit 4 - 5.5 ml.
Study NCT01945450 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antibiotic prophylaxis
Description: antibiotic prophylaxis as following: 24 hours coverage with Ampicillin 2 grams\*4, Gentamycin 240 mg\*1, Clindamycin 600 mg\*3
Study NCT01945450 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ampicillin
Study NCT01945450 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gentamycin
Study NCT01434316 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dinaciclib
Description: Given IV
Study NCT01434316 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Veliparib
Description: Given PO
Study NCT01230125 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mapracorat
Description: Instill study medication into study eye per dosing instructions for 14 days
Study NCT01230125 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Instill study medication into the study eye per dosing instructions for 14 days
Study NCT04388371 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glutamine
Description: Glutamine will be administered by IV injection prior to PET imaging.
Study NCT00482352 — intervention group
Intervention type: OTHER
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT02283177 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: crenolanib
Study NCT02283177 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Study NCT02283177 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daunorubicin
Study NCT02283177 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: idarubicin
Study NCT02262182 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: KP group
Study NCT02262182 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: KM group
Study NCT02044328 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icotinib
Description: Icotinib is administered 125 mg three times per day.
Study NCT04613401 — intervention group
Intervention type: OTHER
Intervention: questionnaire (observational study)
Description: questionnaire about hospitalisation rates, complications (bleeding, infection, thrombosis), quality of life (Kansas-Score), depression (PHQ8)
Study NCT01945450 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clindamycin
Study NCT00903877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T3
Description: Patients receive T3 in a dose of 25mcg and 50mcg
Study NCT01600963 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arm A Double-blind Phase: TMC207
Description: Type=exact number, unit=mg, number=400 mg for the first 2 weeks and 200 mg 3 times per week for the remainder of the treatment period, form=tablet, route=oral administration.
Study NCT04572516 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BTX A Topical
Description: In group A (topical group) ,topical application in the form of merocel soaked with 20 units of BTX_A (2ml) will be placed at each side of the nasal cavity for 30 minutes.
Study NCT04572516 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BTX A Injection
Description: In group B (injected group), 20 units of BTX_A(2ml) will be injected submucosally in each inferior turbinate using insulin syringe needle after local anesthesia using 10% xylocaine spray .
Study NCT03166631 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 754091
Description: Part B
Study NCT03542357 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Calcitonin Gene Related Peptide
Description: CGRP is given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan
Study NCT03542357 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcitonin Gene Related Peptide
Description: CGRP is given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan
Study NCT01340482 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KRN23
Description: Subjects will receive escalating doses of KRN23 administered by SC injections every 28-days (up to 4 doses) based on a dosing algorithm and discretion of the investigator and sponsor.
Study NCT02026713 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: quit smoking for a 2 weeks period
Description: evaluate the platelet reactivity after 15 days by quit smoking
Study NCT02026713 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: quit smoking for a 2 weeks period
Description: evaluate the platelet reactivity after 15 days by quit smoking
Study NCT02701322 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medical clown
Study NCT04668612 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dual-bolus
Description: Dual-bolus (50/50% with second part over 2 hours) for all meals after 6:00 p.m.
Study NCT04668612 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard bolus
Description: Standard boluses for all meals
Study NCT04814017 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radial Shock-Wave Therapy
Description: Radial shock-wave therapy was applied in 1.0-4.0 bar intensity, 10-15 hz frequency interval. 300-700 pulse for a trigger point, 1500-3000 pulse for a muscle. Intensity, frequency and pulse increased every session regularly beginning from minimal taking patients tolerance into consideration. Trigger points in the upper, middle and lower trapezius, supraspinatus, infraspinatus and levator scapula muscles were treated. Neck and upper back muscle static stretching exercises were teached to patients as home exercise program. The patients were asked to do each stretching exercise given as a home-based program every day, 3 times a day and 3 repetitions. The exercise program consisted of static neck lateral flexors stretching, shoulder posterior capsule stretching and apley stretching exercises. Exercise booklets were prepared and given to the patients.
Study NCT04814017 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Control
Description: Neck and upper back muscle static stretching exercises were teached to patients as home exercise program. The patients were asked to do each stretching exercise given as a home-based program every day, 3 times a day and 3 repetitions. The exercise program consisted of static neck lateral flexors stretching, shoulder posterior capsule stretching and apley stretching exercises. Exercise booklets were prepared and given to the patients.
Study NCT01662622 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: The design of experiment is referred to the Dixon up-and-down method. The first subject was designed to receive end-tidal sevoflurane concentration of 1.7%. For each subject, 30 min interval time was given. The isoelectric EEG was considered as significant when the isoelectric state last for more than 1min. The maximal burst suppression rate was recorded if isoelectric EEG was not reached. Heart rate and MAP, were recorded 2 and 1min before and 3 min after skin incision. Adrenergic reflexes positive cases were counted.
Study NCT02977065 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin 20mg
Description: PO daily for 4weeks
Study NCT02977065 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg + CKD-519 50 mg
Description: PO daily for 4weeks
Study NCT02977065 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg + CKD-519 100 mg
Description: PO daily for 4weeks
Study NCT02977065 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg + CKD-519 200 mg
Description: PO daily for 4weeks
Study NCT02977065 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin 10 mg
Description: PO daily for 4weeks
Study NCT02977065 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10 mg + CKD-519 100 mg
Description: PO daily for 4weeks